Home Nav
Nextech Invest Logo

Global Oncology Investment Expertise

We are a global investment advisor in healthcare with a focus on oncology. Nextech is run by an experienced team of industry experts and supported by leading key opinion leaders in oncology.

We deploy our expertise to invest equity in cancer companies with game changing discoveries in the fields of therapeutics, medical technologies and diagnostics.

Executive Management
Scientific Advisory Board
Executive Management
Executive Management

Portfolio Companies

Game Changing Cancer Companies

  • Agensys

    Full Exit

    Fully human antibody drug conjugates for pancreatic cancer.

  • Blueprint

    Preclinical

    Highly selective kinase inhibitors for genomically defined cancer subsets

  • Ganymed

    Full Exit

    Ideal monoclonal antibodies for cancer treatment.

  • ImaginAB

    Clinical Phase I

    Antibody fragments for imaging of cancer.

  • MacroGenics

    IPO

    Antibodies for cancer immunotherapy.

  • Molecular HD

    Market

    Cancer genotyping for targeted cancer therapies.

  • Palyon

    Market

    Implantable drug pumps for palliative care and diabetes.

  • Peloton

    Preclinical

    Small-molecule programs with a distinct target and mechanism of action.

  • Sunesis

    Clinical Phase III

    Small molecules for acute myeloid leukemia.

  • Telormedix

    Sale of shares

    Targeted immunity in cancer and other diseases.

  • TetraLogic

    IPO

    Small molecule Smac mimetics for treatment of cancers.

  • TRACON

    Clinical Phase II

    Antibodies targeting endoglin in cancer angiogenesis.

Corporate Presentation

Get it now.

  • 14.10.2014

    Nextech Invest announces first closing of...

  • 06.10.2014

    Sunesis announces results from pivotal phase...

Corporate Presentation

Get it now.

Portfolio Companies

Game Changing Cancer Companies

  • Agensys

    Full Exit

    Fully human antibody drug conjugates for pancreatic cancer.

  • Blueprint

    Preclinical

    Highly selective kinase inhibitors for genomically defined cancer subsets

  • Ganymed

    Full Exit

    Ideal monoclonal antibodies for cancer treatment.

  • ImaginAB

    Clinical Phase I

    Antibody fragments for imaging of cancer.

  • MacroGenics

    IPO

    Antibodies for cancer immunotherapy.

  • Molecular HD

    Market

    Cancer genotyping for targeted cancer therapies.

  • Palyon

    Market

    Implantable drug pumps for palliative care and diabetes.

  • Peloton

    Preclinical

    Small-molecule programs with a distinct target and mechanism of action.

  • Sunesis

    Clinical Phase III

    Small molecules for acute myeloid leukemia.

  • Telormedix

    Sale of shares

    Targeted immunity in cancer and other diseases.

  • TetraLogic

    IPO

    Small molecule Smac mimetics for treatment of cancers.

  • TRACON

    Clinical Phase II

    Antibodies targeting endoglin in cancer angiogenesis.

  • Agensys

    Full Exit

    Fully human antibody drug conjugates for pancreatic cancer.

  • Blueprint

    Preclinical

    Highly selective kinase inhibitors for genomically defined cancer subsets

  • Ganymed

    Full Exit

    Ideal monoclonal antibodies for cancer treatment.

  • ImaginAB

    Clinical Phase I

    Antibody fragments for imaging of cancer.

  • MacroGenics

    IPO

    Antibodies for cancer immunotherapy.

  • Molecular HD

    Market

    Cancer genotyping for targeted cancer therapies.

  • Palyon

    Market

    Implantable drug pumps for palliative care and diabetes.

  • Peloton

    Preclinical

    Small-molecule programs with a distinct target and mechanism of action.

  • Sunesis

    Clinical Phase III

    Small molecules for acute myeloid leukemia.

  • Telormedix

    Sale of shares

    Targeted immunity in cancer and other diseases.

  • TetraLogic

    IPO

    Small molecule Smac mimetics for treatment of cancers.

  • TRACON

    Clinical Phase II

    Antibodies targeting endoglin in cancer angiogenesis.

Executive Management
Scientific Advisory Board
Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close